New combo therapy offers hope for hard-to-treat GI cancers
NCT ID NCT06065371
First seen Jan 09, 2026 · Last updated May 16, 2026 · Updated 25 times
Summary
This early-phase study tests a combination of two drugs, sacituzumab govitecan and capecitabine, in people with advanced gastrointestinal cancers (such as stomach, colon, or pancreatic cancer) that have stopped responding to standard treatments. The main goal is to find a safe and tolerable dose. About 20 adults will take part, and researchers will also look at how well the treatment works and whether a marker called Trop-2 is linked to outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTROINTESTINAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Henry Ford Cancer-Detroit
RECRUITINGDetroit, Michigan, 48201, United States
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.